ClinicalTrials.gg
Active, not recruitingNCT02324283Updated Apr 5, 2024Results posted

Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia

An interventional study of desflurane and propofol in Lung Cancer, sponsored by Juntendo University. Active, not recruiting at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by Juntendo University · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 102 studies in Lung Neoplasms with a site in Japan — 27 open to participants now, 48 under way, 25 of them phase 3. Lung Neoplasms · Japan.

Enrollment
67th of 95
80 · median 200
Started
2012
with 5 others
No phase
2 of 102
none open now
Primary completion
2016-06
later than 0 of 47 live
Registered
35th of 102
by date

Among the 102 studies in Lung Neoplasms with a site in Japan, this one is the 67th largest by enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2012, is one of 2 with no phase, reaches primary completion later than 0 of the 47 other live ones, and was the 35th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

27 of the 102 studies in Lung Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Lung Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

Which is more adequate general anesthetic agent, desflurane or propofol, for emergence and recovery time, and perioperative oxygenation in lung resection surgery?

Read the detailed description

The investigators plan to investigate the effects of desflurane on oxygenation (prevention of HPV) of OLV compare with propofol which is used in general anesthesia for lung resection.

Transesophageal echocardiography (TEE) wiill be used to measure pulmonary blood flow during surgery visible and successively. To confirm the effect of HPV by measuring the change in pulmonary blood flow. The correlation between the blood oxygen concentration and attenuation of blood flow will be investigated.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • one-lung ventilation, oxygenation
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients agree to participate in the study
  • Patients undergoing lung cancer surgery requiring one-lung ventilation.
  • Physical Status Class 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Patients with any of the following will be excluded from lung cancer patients.
  • Classification more than 2
  • Respiratory dysfunction Vital Capacity or percent predicted is less than 50 %
  • Pulmonary hypertension with mean pulmonary arterial pressure more than 30 mmHg
  • Coagulation dysfunction
  • The administration of and agents within 3 months prior to surgery
  • Infection with active inflammation
  • Pneumonectomy patients
  • Cases of epidural anesthesia is
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Desflurane

    Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1\~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.

    Drug: desflurane

  • Active comparator
    Propofol

    Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1\~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.

    Drug: propofol

Interventions

  • Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia. Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.

    Also known as: Suprene

  • Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.

    Also known as: Diprivan

06

What researchers measure

Primary outcomes

  1. Oxygenation

    Arterial blood gases are monitored.Pulmonary blood flow is measured using transesophageal echocardiogram.

    Time frame: prior to surgery to one-hour after extubation

Secondary outcomes

  1. Rapidity of Emergence From Anesthesia

    Time to extubation and orientation, where the patient is.

    Time frame: one minute after cessation of anethetic agents to one hour after extubation

  2. Quality of Consiousness

    quality of consciousness will be assessed using Aldrete score

    Time frame: after extubation

  3. Postoperative Nausea and Vomiting

    degree of nausea and frequency of vomiting

    Time frame: on the postoperative day 1

07

Results

Posted Apr 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneDesfluranePropofol
Started4040
Completed4040
Not completed00

Outcome measures

PrimaryOxygenation

Arterial blood gases are monitored.Pulmonary blood flow is measured using transesophageal echocardiogram.

Time frame:
prior to surgery to one-hour after extubation
Reported as:
Mean · mmHg
Oxygenation
mmHgDesfluranePropofol
Preoperative87.4 ± 12.085.7 ± 11.3
DLV(pre)469.9 ± 79.8483.8 ± 91.7
OLV(15min)178.5 ± 95.0214.7 ± 114.2
OLV(30min)137.7 ± 78.2161.6 ± 95.4
OLV(45min)140.7 ± 86.6171.57 ± 95.6
DLV(post)429.9 ± 98.3427.49 ± 111.6
5min after exT131.63 ± 44.2134.88 ± 64.0
30min after exT125.71 ± 45.3125.65 ± 32.91
60min after exT130.49 ± 45.0137.2 ± 36.0
SecondaryRapidity of Emergence From Anesthesia

Time to extubation and orientation, where the patient is.

Time frame:
one minute after cessation of anethetic agents to one hour after extubation
Reported as:
Mean · seconds
Rapidity of Emergence From Anesthesia
secondsDesfluranePropofol
Rapidity of Emergence From Anesthesia252.3 ± 156.3269.5 ± 142.9
SecondaryQuality of Consiousness

quality of consciousness will be assessed using Aldrete score

Time frame:
after extubation
Reported as:
Number · participants
Quality of Consiousness
participantsDesfluranePropofol
Quality of Consiousness20
SecondaryPostoperative Nausea and Vomiting

degree of nausea and frequency of vomiting

Time frame:
on the postoperative day 1
Reported as:
Count of participants · Participants
Postoperative Nausea and Vomiting
ParticipantsDesfluranePropofol
Postoperative Nausea and Vomiting1510

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Desflurane0/40 (0%)0/40 (0%)0/40 (0%)
Propofol0/40 (0%)0/40 (0%)0/40 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DesfluranePropofolTotal
<=18 years000
Between 18 and 65 years353570
>=65 years5510
Age, Continuous
Age, Continuous(years)DesfluranePropofolTotal
Mean64.5 ± 9.763.2 ± 6.663.8 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)DesfluranePropofolTotal
Female191635
Male212445
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)DesfluranePropofolTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)DesfluranePropofolTotal
Japan404080
08

Study locations

1 site
  • University of Juntendo
    Bunkyo-ku, Tokyko 113-8421, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jun 2016 and a completion of Dec 2024. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2024, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2014
First posted
Dec 24, 2014
Start
Oct 2012
Primary completionActual
Jun 2016
CompletionEst.
Dec 2024
Results first posted
Apr 5, 2024
Last update
Apr 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02324283
Lead sponsor
Juntendo University
Responsible party
Sponsor
First posted
Dec 24, 2014
Start date
Oct 2012
Primary completion
Jun 2016
Completion
Dec 2024 (estimated)
Results posted
Apr 5, 2024
Last update
Apr 5, 2024

Study contacts

Eiichi Inada, M.D.
principal investigator · Juntendo University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desflurane · Propofol

Start the discussion